Latest in Pharmaceuticals & Biotech

wqow.com
344 words

Columbia County confirms at least 3 measles cases

PORTAGE, Wis. (WKOW) — Columbia County Public Health has confirmed at least three cases of measles linked to a laboratory-confirmed case in another Wisconsin county. All confirmed and suspected cases identified so far have been among people who were not vaccinated…

prnewswire.com
80 words

Verismo Therapeutics Presents Preclinical Data at SITC 2026 Demonstrating Enhanced Tumor Control and Reduced Cytokine Release with SynKIR™-110 KIR-CAR Compared to Conventional CAR T

Nov 03, 2026, 19:00 ET SynKIR™-110 demonstrated faster tumor control with approximately 10-fold lower IFNγ and 30-fold lower TNFα and IL-2 production compared to CD28-based single-chain CAR T in preclinical models Preclinical in vivo data showed reduced exhaustion of tumor-infiltrating SynKIR™-110 T cells…

prnewswire.com
94 words

Verismo Therapeutics to Present First-in-Human SynKIR™-310 KIR-CAR Clinical Data Showing Robust Antitumor Activity and Favorable Safety Profile in Oral Presentation at 68th ASH Annual Meeting

Nov 04, 2026, 19:00 ET Interim clinical data of SynKIR™-310, a CD19-targeted KIR-CAR T therapy, showed no CRS, ICANS, or DLT in the first two dose levels, coupled with robust antitumor activity in patients with relapsed or refractory B-cell non-Hodgkin Lymphoma (B-NHL) Verismo…

Pharmaceuticals & Biotech

Pipelines, trials, approvals, safety, manufacturing, and next‑gen therapies.

  • 7 Subtopics
  • 9 Tracked terms
  • Last 30 days Feed window

Inside Pharmaceuticals & Biotech

Discovery & Preclinical Targets, assays, animal models, and early safety/tox studies before human trials.
Clinical Trials (Phases I–IV) Design, endpoints, enrollment, interim reads, and post‑market surveillance.
Approvals, Safety & REMS FDA/EMA decisions, boxed warnings, pharmacovigilance, and label changes.
Generics & Biosimilars Access, interchangeability, litigation, and pricing dynamics for follow‑ons.
Vaccines & Immunization Platforms (mRNA, viral vector), boosters, schedules, and cold‑chain supply.
Cell & Gene Therapies CAR‑T, CRISPR, in vivo delivery, manufacturing, and long‑term follow‑up.
Manufacturing & Supply APIs, sterile fill‑finish, shortages, and quality systems across the supply chain.

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.